Skip to main content
TipRanks
Go Ultimate75% OFF

Victrex (VTXPF) Q4 2025 Earnings Report

1 Followers

VTXPF Q4 2025 EPS Results

Actual EPS
$0.23
Consensus EPS
$0.23
Beat/Miss
Met expectations
One Year Ago EPS
$0.45

VTXPF Q4 2025 Revenue Results

Actual Revenue
$192.87M
Expected Revenue
$92.83M
Beat/Miss
Beat by +$100.03M
YoY Revenue Growth
-3.23%

Earnings Announcement Details

Quarter
Q4 2025
Date
12/02/2025
Time
Before Open
Conference Call
Tuesday, December 2, 2025
VTXPF Upcoming Earnings

Victrex's next earnings date is estimated for December 1, 2026, based on past reporting schedules.

Q4 2025 Earnings Call Audio

No earnings call audio is available for this earnings event.

Q4 2025 Earnings Slide Deck

No slide deck is available for this earnings event.

Q4 2025 Earnings Call Summary

Q4 2025
Earnings Call Date:Dec 02, 2025|% Change Since:59.03%|
Earnings Call Sentiment|Neutral

The earnings call presented a mixed picture with notable achievements in volume growth and cash conversion, while facing significant challenges due to currency impacts, weaker medical spine performance, and losses from the China facility. The profit improvement plan and diversification in medical revenues are positive steps, but current financial challenges weigh heavily.

Company Guidance

In the call, Victrex provided guidance on various financial metrics for fiscal year 2025 and the outlook for 2026. The company reported a 12% increase in sales volume, reaching 4,164 tonnes, mainly driven by value-added resellers (VARs) and the Energy & Industrial sector. Despite the robust volume growth, underlying profit before tax (PBT) was impacted by an adverse currency effect of GBP 8 million, resulting in a 21% decrease to GBP 46.4 million. However, cash conversion was strong at 121%, benefiting from efficient working capital management. Capital expenditures (CapEx) saw a significant reduction, reflecting the conclusion of recent investment phases. For fiscal 2026, Victrex is targeting low to mid-single-digit volume growth and aims to achieve at least GBP 10 million in savings through a profit improvement plan. Gross margin for FY '26 is expected to be flat to slightly ahead, with the China manufacturing facility remaining a focus for operational improvements. The company will maintain its dividend and review its capital allocation policy, aiming to retain a strong balance sheet with a net debt-to-EBITDA range of 0.5x to 1x.

  • Strong Volume GrowthSales volume increased by 12% to 4,164 tonnes, primarily driven by value-added resellers and Energy & Industrial sectors.
  • Cash Conversion PerformanceOperating cash conversion was strong at 121%, reflecting effective working capital management and a significant reduction in capital expenditures.
  • Profit Improvement PlanAnnounced a profit improvement plan targeting GBP 10 million in savings, leveraging self-help actions and foundational investments in infrastructure and technology.
  • Diversified Medical BusinessNon-spine medical revenues comprised 74% of the total medical revenue, up from 25% in 2015, indicating diversification within the medical sector.

VTXPF Earnings History

VTXPF earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Dec 01, 20262026 (Q4)―-0.23――
May 11, 20262026 (Q2)―0.230.29-23.21% (-0.07)
Dec 02, 20252025 (Q4)0.230.230.45-49.13% (-0.22)
May 12, 20252025 (Q2)0.330.290.35-17.04% (-0.06)
Dec 03, 20242024 (Q4)0.450.450.48-4.95% (-0.02)
May 13, 20242024 (Q2)―0.350.63-44.10% (-0.28)
Dec 05, 20232023 (Q4)0.480.480.63-23.85% (-0.15)
May 09, 20232023 (Q2)0.630.630.631.05% (+0.01)
Dec 06, 20222022 (Q4)―0.630.4830.96% (+0.15)
May 09, 20222022 (Q2)―0.630.621.92% (+0.01)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed